N/A N=66 Asthma Link: A Real World Application of School Supervised Asthma Therapy
Childhood Asthma
Primary: Recruitment Procedures Assessed by Number of Patients Screened — 143; 208 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=48 Perceived Social Support, Heart Rate Variability, and Hopelessness in Patients With Ischemic Heart Disease
Ischemic Heart Disease
Primary: State Hopelessness — 1.25 units on a scale — p=<0.05
Phase 1 N=74 Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine
Major Depressive Disorder
Primary: Number of Subjects With Adverse Events as a Measure of Safety and Tolerability of (2R,6R)-Hydroxynorketamine — 1; 0; 1; 1 Participants
Phase 2 N=45 Evaluation of Nicotinamide Riboside in Prevention of Small Fiber Axon Degeneration and Promotion of Nerve Regeneration
Small Fiber Neuropathy
Primary: Denervation of Skin — 0.1; 0.1 percent change — p=0.33
N/A N=524 Sigh Ventilation to Increase Ventilator-Free Days in Victims of Trauma at Risk for Acute Respiratory Distress Syndrome
Acute Respiratory Distress Syndrome
Primary: Ventilator-free Days (VFDs) — 18.4; 16.1 days
Phase 2 N=48 Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS
Amyotrophic Lateral Sclerosis (ALS)
Primary: Number of Patients With at Least One Treatment Emergent Adverse Events — 36; 12 Participants
Phase 2 N=17 Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia
Acute Myeloid Leukaemia
Primary: Dose Limiting Toxicity (DLT) (Phase I - Dose Escalation) — 0; 1; 1 Participants
Phase 2 N=107 Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients
Systemic Lupus Erythematosus (SLE)
Primary: Percentage of Participants With SLE Responder Index (SRI)-4 Response Status at Week 29 With Reduced Steroid Dose Maintained Between Weeks 17 and 29 — 15; 3; 8; 6…
Phase 1 N=24 Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004)
Renal Dialysis · Kidney Failure, Chronic
Primary: Part 1: Percentage of Participants With Any Adverse Event (AE) — 16.7; 57.1; 66.7; 60.0 Percentage of Participants
Phase 1 N=12 Relative Bioavailability Study of PF-07321332/Ritonavir Oral Powder Relative to the Commercial Tablets in Healthy Participants
Bioavailability
Primary: AUCinf of Nirmatrelvir Following the Administration of Nirmatrelvir/Ritonavir in Different Delivery Vehicles Under Fasted Conditions — 28670; 30780; 33170; 36020…
Phase 2 N=284 A Study of Armour® Thyroid Compared to Synthetic T4 (Levothyroxine) in Previously Hypothyroid Participants
Hypothyroidism · Thyroid Disease · Euthyroid
Primary: Percentage of Participants With a Sustained TSH Response — 60.76; 75.92 percentage of participants
Phase 4 N=76 The Role of Quadratus Lumborum Blocks Following Minimally Invasive Hysterectomy
Pain, Postoperative
Primary: Pain as Assessed by the Quality of Recovery (QOR-40) Validated Questionnaire — 30.0; 31.1 score on a scale
Phase 2 N=15 Guanfacine to Reduce Relapse Risk in Women With Alcohol Use Disorder (AUD)
Alcohol Abstinence
Primary: Percentage of Days Abstinent — 74.7; 50.6 percentage of days abstinent — p=<0.03
N/A N=29 4DCT Imaging for Improved Diagnosis and Treatment of Wrist Ligament Injuries
Scapholunate Interosseous Ligament Injury
Primary: Equivalency of 4DCT-based Treatment Plan to Arthroscopic-based Treatment Plan. — 5; 14; 11 Participants
Phase 3 N=33 Study of the Efficacy and Safety of Somatropin in Japanese Participants With PWS
Prader-Willi Syndrome
Primary: Change From Baseline to Month 12 in Lean Body Mass Measured by Dual-Energy X-ray Absorptiometry (DEXA): Adult Cohort — 3.09 Percentage of body mass